Clinical Trial Update: A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients [Phase 2]

View source ↗

Summary

Phase 2 safety and tolerability evaluation of two 10-week oral dose regimens of PF-04494700 in patients with Alzheimer's disease. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• PF-04494700

Snippet

Sponsor: Pfizer | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED